Alexion Pharmaceuticals to pay $21M to resolve FCPA case

Alexion

Alexion Pharmaceuticals will pay $21 million to resolve SEC charges that it violated the books and records and internal accounting controls provisions of the FCPA concerning bribes made by subsidiaries to foreign government officials.

lock iconTHIS IS MEMBERS-ONLY CONTENT. To continue reading, choose one of the options below.